Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...
This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
